Format

Send to

Choose Destination
Pharm Res. 2019 Oct 15;36(12):163. doi: 10.1007/s11095-019-2697-1.

Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?

Author information

1
Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands. m.crombag@nki.nl.
2
Division of Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands. m.crombag@nki.nl.
3
Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
4
Department of Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands.
5
Department of Medical Oncology and Hematology, Cantonal Hospital, St Gallen, Switzerland.
6
Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands.
7
Division of Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
8
Department of Pharmacy and Radboud Institute of Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
9
Utrecht Institute for Pharmaceutical Sciences (UIPS), Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, the Netherlands.
10
Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Abstract

PURPOSE:

There is ongoing concern regarding increased toxicity from paclitaxel in elderly patients, particularly of severe neutropenia. Yet, data so far is controversial and this concern is not supported by a clinically relevant age-dependent difference in pharmacokinetics (PK) of paclitaxel. This study assessed whether age is associated with increased risk for paclitaxel-induced neutropenia.

METHODS:

Paclitaxel plasma concentration-time data, pooled from multiple different studies, was combined with available respective neutrophil count data during the first treatment cycle. Paclitaxel pharmacokinetic-pharmacodynamic (PK-PD) data was modeled using a non-linear mixed effects approach and a semiphysiological neutropenia model, where systemic paclitaxel exposure was linked to reduced proliferation of neutrophils. The impact of age was evaluated on relevant variables in the model, using a significance threshold of p < 0.005.

RESULTS:

Paclitaxel PK-PD data was evaluated from 300 patients, with a median age of 65 years (range 23-84 years), containing 116 patients ≥70 years (39%). First cycle neutrophil counts were adequately described by a threshold effect model of paclitaxel on the proliferation rate of neutrophils. Age as a continuous or dichotomous variable (≥70 versus <70 years) did not significantly impact sensitivity of the bone marrow to paclitaxel nor the average maturation time of neutrophils (both p > 0.005), causing a decline in the respective interindividual variability of <1%.

CONCLUSION:

Results from this large retrospective patient cohort do not suggest elderly patients to be at an increased risk of developing paclitaxel-associated neutropenia during the first treatment cycle. Reflexive dose reductions of paclitaxel in elderly patients are unlikely to improve the risk of severe neutropenia and may be deleterious.

KEYWORDS:

age differences; elderly patients; neutropenia; paclitaxel; pharmacokinetics-pharmacodynamics

PMID:
31617004
DOI:
10.1007/s11095-019-2697-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center